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BACKGROUND: Recently, the vitamin D receptor (VDR) polymorphism FokI was shown to be associated with susceptibility to ovarian
cancer. We aimed to examine whether VDR FokI polymorphisms influence the survivals of patients with epithelial ovarian cancer
(EOC).
METHODS: VDR polymorphisms from FokI in 101 patients with EOC were genotyped by sequencing. Overall survival was compared
between FokI single nucleotide polymorphism using Kaplan–Meier survival curves with log-rank tests and the Cox proportional
hazard model adjusted for ages, stages, histology, and existence of residual tumour.
RESULTS: The FokI C/C genotypes were associated with better prognosis compared with the C/T and T/T genotypes (log-rank test:
P¼0.008; adjusted hazard ratio, 0.18; 95%CI 0.05–0.61; P¼0.006).
CONCLUSIONS: These results suggest that the VDR polymorphisms from the FokI genotype may be associated with improved
prognosis of patients with EOC.
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Recently, a meta-analysis showed that patients with one of single
nuclear polymorphisms vitamin D receptor (VDR), the
FokI (rs2228570) TT genotype, had a significantly higher risk for
developing ovarian cancer as well as prostate, breast, skin, non-
Hodgkin lymphoma, and colorectal cancer compared with its
CC genotype (Raimondi et al, 2009). Moreover, combined results
from four case–control studies showed almost the same results
regarding enhanced susceptibility to ovarian cancer (Tworoger
et al, 2009). However, the risk of developing ovarian cancer based
on FokI genotype is minor (Lurie et al, 2007), and study findings
are controversial (Clendenen et al, 2008).
Recently, Heist et al (2008) showed that the T allele of VDR FokI
polymorphisms was associated with significantly worse survival in
patients with advanced non-small cell lung cancer, which is the
first report to show a relationship between VDR polymorphisms
and prognosis of patients with cancer. Although some articles
show an association between FokI polymorphisms and suscept-
ibility to epithelial ovarian cancer (EOC), no report has shown a
relationship between FokI polymorphisms and survival of patients
with EOC. Therefore, we investigated whether VDR FokI
polymorphisms influenced the prognosis of patients with EOC.
MATERIALS AND METHODS
Patients
This prospective cohort hospital-based study to detect important
gene mutations in ovarian cancer was approved by the Ethics
Committee for Biomedical Research of the Jikei Institutional
Review Board, Jikei University School of Medicine, Tokyo, Japan.
As post-hoc analysis, we performed to re-examine VDR FokI
polymorphisms in this cohort. Between September 1996 and
January 2009, approximately 600 patients with EOC took surgery.
Of these, approximately 300 had Paclitaxel–Carboplatin treatment
as a first line chemotherapy. Of these, approximately 250 patients
provided informed consent. Of these, approximately 200 samples
showed more than 80% of cancer cells. Of these, 125 samples were
enriched DNA by laser capture micro-dissection or trimming with
needle. Of these, 24 were not selected from this study because DNA
specimens were not available. Thus, 101 patients with EOC were
included in this study: Clinical information was abstracted from
clinical and surgical charts. Postoperative stages were determined
by International Federation of Gynecology and Obstetrics (FIGO)
classification (Kikkawa et al, 2006). Patients were periodically
(every 0.5–2 months) examined on an outpatient basis to make
sure they had not relapsed.
Samples
In all cases, tumour samples from the primary site, but not
metastatic sites, were stored at  801C after excision. Cancer
tissue was divided into two specimens: one for pathological
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sconfirmation, in which the sample was composed of more than
80% cancer cells, and the other for DNA extraction. Peripheral
blood samples were collected during the preoperative period from
10 of the same patient’s group to confirm whether alteration of
sequence was due to either genomic polymorphisms or somatic
mutations.
Polymorphisms of the VDR gene
DNA was extracted from the fresh frozen tumour and peripheral
blood samples using QIAcube (Qiagen, Tokyo, Japan) following
the manufacturer’s protocol. DNA fragments of FokI were
amplified by polymerase chain reaction (PCR) using the following
primers (forward/reverse): ctccgaaggcactgtgctcaggcct/atggaaa-
caccttgcttcttctccctc; sequence, ggcctgggccctggggagat; parameters:
denaturation at 981C for 1min, followed by 30 cycles at 981C
for 10s, annealing at 681C for 4min, and the stopping reaction
at 161C.
The PCR products were incubated with rAPid alkaline
phosphatase (Roche Diagnostics, Mannheim, Germany) and
Exonuclease I (New England BioLabs, Ipswich, MA, USA) at
371C for 30min, then 801C for 15min. Using Big Dye Terminator
v3.1 Cycle Sequencing kit (Applied Biosystems, Tokyo, Japan), the
aliquots were incubated under the following conditions: 961C for
5min; 25 cycles at 961C for 10s, 501C for 5s, and 601C for 2min.
Treated PCR products were sequenced with the ABI PRISM 3700
Genetic Analyzer (Applied Biosystems, Foster City, CA, USA).
Sequencing was confirmed with independent duplicate analyses in
20 samples for quality control to find no discrepancy. Genotyping
success rate was 69%, although genotyping success rate improved
to 100% by repeated measure. Genotyping was performed by ST
and CN, who were blinded to clinical information.
Statistical analysis
The analysis of variance and w
2 test were used to evaluate
differences in patients’ characteristics stratified by VDR genotypes.
Overall survival curves were drawn using the Kaplan–Meier
method and compared by VDR polymorphisms using log-rank
tests. Cox proportional hazard models were fitted for multivariate
analysis using postoperative stages (stages I–IV), histology
(endometrioid, clear cell, serous mucinous, mixed mesodermal),
residual tumour (none, o2cm, X2cm), and ages. Adjusted hazard
ratios (AHR) and 95% confidence intervals (CI) were computed.
All statistical analyses were performed using STATA 9.1 (STATA
Corp., College Station, TX, USA). Po0.05 was considered
statistically significant.
RESULTS
Patients’ characteristics
Patients ranged in age from 42–64 years. When classified under
FIGO staging, around 53% of the patients had advanced stages of
disease (stages III–IV). We confirmed that the polymorphism FokI
was common between the tumour and peripheral blood samples
obtained from the same 10 patients, suggesting genomic altera-
tions, but not somatic mutations. Genotype frequencies of the VDR
polymorphisms based on tumour samples were as follows: FokIC / C ,
35%; C/T, 55%; and TT, 10%. Patients’ characteristics were not
significantly different among FokI genotypes (Table 1).
FokI polymorphisms and overall survival
All 101 patients were followed for a median of 85 months; 45 (45%)
relapsed and 28 (28%) died of EOC. Kaplan–Meier survival curves
showed that the FokI C/C genotype was associated with a better
prognosis. At 30 months after surgery, 90% of patients with FokI
C/C genotype were still alive; in contrast, only 66% of patients with
C/T and T/T were alive (Figure 1A). When cancer stage was
restricted to stage I, there was no significant difference between C/C
and C/T plus T/T genotypes (Figure 1B). When cancer stages were
restricted to II–IV, 84% of patients with FokI C/C were still alive;
in contrast, only 50% of patients with C/T and T/T were still alive
(Figure 1C).
Cox proportional hazard models with multivariate
adjustment
Cox proportional hazard models were computed to determine the
significance of FokI with adjustment for postoperative stages,
histology, existence of residual tumour and ages (Table 2).
Without multivariate analysis, patients with FokI C/C genotype,
stage I disease, or without residual tumour after surgery did show a
significantly reduced crude hazard ratio. Even with multivariate
analysis, patients with the FokI C/C genotype showed significantly
Table 1 Patients’ characteristics stratified by FokI genotype
Variable number (%) Total 101 Fok I C/C 35 (35) Fok I C/T 56 (55) Fok I T/T 10 (10) P value
Age, year (mean±s.d.) 53.1±10.6 52.0±8.8 54.6±12.1 48.1±5.6 0.18
a
Histological type: Number (%) 0.54
b
Endometrioid 21 9 (43) 11 (52) 1 (5)
Clear cell 35 10 (29) 22 (63) 3 (9)
Serous 38 12 (32) 20 (53) 6 (16)
Mucinous 6 4 (67) 2 (33) 0
Mixed mesodermal 1 0 1 0
FIGO staging 0.36
b
I (A, B, C) 41 15 (36) 22 (54) 4 (10)
II (A, B, C) 6 1 (17) 3 (50) 2 (33)
III (A, B, C) 44 16 (36) 26 (59) 2 (5)
IV 10 3 (30) 5 (50) 2 (20)
Residual tumour
c 0.43
b
None 69 25 (36) 36 (52) 8 (12)
o2cm 12 3 (25) 7 (58) 2 (17)
X2cm 20 7 (35) 13 (65) 0 (0)
Abbreviation: FIGO¼Federation of Gynecology and Obstetrics.
aANOVA.
bw
2 test.
cExistence and size of residual tumour after surgery.
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sbetter prognostic markers: AHR, 0.18; 95% CI, 0.05 to 0.61;
P¼0.006.
DISCUSSION
In this study, we found that the VDR FokI C/C genotype was
associated with a better overall survival rate in patients with EOC
than a combination of FokI C/T and FokI T/T, even after
adjustment for cancer stage, histology, existence of residual
tumour and age. Arai et al (1997) showed that compared with
the FokI T/T genotype, FokI C/C had 1.7-fold greater function of
vitamin D-dependent transcriptional activation of a reporter
construct under the control of a vitamin D response element in
transfected HeLa cells. Similarly, Colin et al (2000) showed a
significantly lower (50%) effective dose of 1,25-(OH)2D3 in the
FokI C/C genotype than in FokI C/T genotype. By switching from
ATG (FokI T) to ACG (FokI C) polymorphism, the first potential
start site moves to the 30 direction, resulting in proteins that are
three amino acids shorter and more functional (Gross et al, 1996).
Thus, patients with FokI C/C may react more to vitamin D,
resulting in a higher survival rate.
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Figure 1 Kaplan–Meier curves of overall survival by (A) stages I–IV, (B) stage I, (C) stages II–IV.
Table 2 Cox proportional hazard models
Single-variate analyses Multivariate analysis
Variable Crude HR 95% CI P value AHR 95% CI P value
FokI C/C: 66 0.26 0.09–0.76 0.014 0.18 0.05–0.61 0.006
FokI C/T or T/T: 35 Reference Reference
Stage I: 41 0.05 0.005–0.42 0.006 0.02 0.002–0.28 0.004
Stage II: 6 0.78 0.14–4.32 0.78 0.76 0.89–6.54 0.81
Stage III: 44 1.32 0.45–3.86 0.62 1.09 0.33–3.61 0.89
Stage IV: 10 Reference Reference
Histology
Endometrioid: 21 0.17 0.02–1.71 0.13 0.05 0.03–0.95 0.04
Clear Cell: 35 0.51 0.06–4.04 0.52 0.53 0.05–5.16 0.58
Serous: 38 0.60 0.08–4.70 0.63 0.08 0.07–0.88 0.04
Mucinous: 6 Reference Reference
Mixed mesodermal: 1 0.27 0.02–4.31 0.35 0.09 0.04–2.10 0.13
Residual tumour
None: 69 Reference Reference
o2cm: 12 5.67 1.84–17.43 0.003 1.73 0.39–7.69 0.47
X2cm: 20 11.19 4.36–28.72 o0.001 4.93 1.31–18.53 0.02
Age 1.06 1.01–1.10 0.005 1.01 0.98–1.05 0.49
Abbreviations: HR¼hazard ratio; CI¼confidence interval; AHR¼adjusted hazard ratio. Adjusted for postoperative stages, postoperative chemotherapy, histology
(endometrioid, clear cell, serous, mucinous, mixed mesodermal), and residual tumour (none, o2cm,X2cm).
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sHigher serum levels of 25-hydroxyvitamin D (25(OH)D) can be
associated with better outcome in EOC, as reported in early stages
of breast, colon, and lung cancer (Zhou et al, 2007; Ng et al, 2008;
Goodwin et al, 2009). Moreover, ecological studies showed that
solar ultraviolet B irradiance was inversely associated with
incidence rates of ovarian cancer (Garland et al, 2006) as well as
survival of patients with ovarian cancer (Grant, 2006), implying a
link between ultraviolet B irradiance, vitamin D, and ovarian
cancer both in susceptibility and survival. A plausible explanation
for why increased sun exposure and higher circulating levels of
vitamin D are associated with a decreased risk of deadly cancers is
as follows (Holick, 2007). Epithelial cells convert the primary
circulating form of vitamin D, (25(OH)D), to its active form, 1,25-
dihydoroxyvitamin D, inside the cells, which bind VDR in their
nucleus to regulate a variety of genes. These genes help prevent
malignant transformation by keeping cellular proliferation and
differentiation within normal ranges. In turn, if a cell becomes
malignant, 1,25-dihydroxyvitamin D can induce apoptosis and
prevent angiogenesis, thereby reducing the potential for the
malignant cell to survive. Vitamin D3 derivative was shown to
induce apoptosis of ovarian cells but not of primary fibroblasts
and to suppress ovarian tumour growth in a mice model (Zhang
et al, 2005; Lange et al, 2009).
There are several limitations to our study. Overall, the sample
size is not large enough to detect significant differences in patients
stratified by histology or stages. We did not use restriction
fragment length polymorphism analysis and directly sequenced
PCR fragments to avoid misclassification as much as possible and
to compensate for the disadvantage of the small sample size.
Moreover, cases were not consecutively selected, which may cause
selection bias. This study was performed as post-hoc analysis of
prospective cohort hospital-based study to detect important gene
mutations in ovarian cancer. Thus, serum 25(OH)D was not
measured, vitamin D and its synergistic effect with VDR
polymorphism were not evaluated. There are other kinds of VDR
polymorphisms, such as Cdx-2 and BsmI, related to disease risks
that have been reported in previous articles, and we need to
expand our range of analysis in the future.
In conclusion, there were significant associations between better
prognosis of patients with EOC and the FokI C/C genotype.
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